AI Terminal
POLAREAN IMAGING PLC
Share Issue/Capital Change • Jan 27, 2023
7850_rns_2023-01-27_0fdb4100-be10-45ac-9aa6-d2e558f02b5f.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0081O
Polarean Imaging PLC
27 January 2023
Polarean Imaging Plc
("Polarean" or the "Company")
Block Listing Six Monthly Return
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
| Name of applicant: | Polarean Imaging Plc | ||||
| Name of scheme: | Polarean Share Option Plan | ||||
| Number and class of securities originally admitted: | 8,000,000 ordinary shares of £0.00037 each | ||||
| Date of admission: | 29 July 2021 | ||||
| Period of return: | From: | 28 July 2022 | To: | 26 January 2023 | |
| Balance of unallotted securities under scheme(s) from previous return: | 4,025,657 | ||||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | ||||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 0 | ||||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 4,025,657 | ||||
| Total number of securities in issue at the end of the period | 213,047,509 | ||||
| Name of contact: | Richard Hullihen, Chief Executive Officer |
| Telephone number of contact: | + 44 (0)20 7933 8780 or [email protected] |
Enquiries:
| Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | ||||
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR | ||||
| Kenneth West, Chairman | |||||
| Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | ||||
| Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) | |||||
| Nick Adams / Nick Harland (Corporate Broking) | |||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | ||||
| Anna Dunphy /Phillip Marriage | Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 | ||||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung function, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform, Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On December 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (xenon Xe 129 hyperpolarized). 129Xe MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.
XENOVIEWTM is a trademark of Polarean, Inc. POL-PR-2201
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRNKABQNBKDFDB